Browsing Schizophrenia and Psychotic Disorders by Title
Now showing items 47-66 of 101
-
Identifying effective characteristics of behavioral weight management interventions for people with serious mental illness: A systematic review with a qualitative comparative analysis
(2021-10)People with serious mental illness (SMI) have identified barriers to engaging in behavioral weight management interventions (BWMIs). We assessed whether BWMIs that addressed these barriers were more effective. First, we ... -
‘If he feels better I'll feel better’ relationships with individuals at high-risk of developing psychosis
(2021-03)A large proportion of individuals with an at-risk mental state (ARMS) live at home and are supported by their families. Recommended treatment includes family intervention (FI), and therefore, understanding relationships ... -
The impact of Patient and Public Involvement in the SlowMo study: Reflections on peer innovation
(2021-09)Background: The SlowMo study demonstrated the effects of SlowMo, an eight-session digitally supported reasoning intervention, on paranoia in a large-scale randomized-controlled trial with 362 participants with schizophre ... -
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
(2019-07)Importance: Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether ... -
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
(2019-06)Background: Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and ... -
Is adjunctive CBT really effective for schizophrenia?
(2019-09)Although antipsychotic medication remains the mainstay of treatment for schizophrenia, medications alone are not always successful. Cognitive– behavioural therapy (CBT) is recommended as an adjunct to pharmacological ... -
Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders?
(2022-08)Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety ... -
Is there a choice to make? A pilot study investigating attitudes towards treatment in an Early Intervention for Psychosis service
(2018-03)Purpose The purpose of this paper is to investigate health care professionals’ (HCPs) and service-users’ (SUs) attitudes towards different treatment options in an Early Intervention for Psychosis (EIP) service as well as ... -
The journey of adolescent paranoia: A qualitative study with patients attending child and adolescent mental health services
(2022-02)Objectives: Paranoia is most likely to emerge in adolescence. In adolescents with mental health disorders, the disruptive effect of paranoia on social relationships could worsen outcomes. However, little is known about ... -
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
(2021-12)The cognitive dysfunction experienced by patients with schizophrenia represents a major unmet clinical need. We believe that enhancing synaptic function and plasticity by targeting kalirin may provide a novel means to ... -
Ketamine for Psychiatric Disorders
(2019-07)This new edition of The ECT Handbook comes six years after the publication of the 3rd edition. In the intervening period there have been no major changes in the practice of electroconvulsive therapy, but continuing research ... -
A life more ordinary: A peer research method qualitative study of the Feeling Safe Programme for persecutory delusions
(2022-07)Background: The Feeling Safe Programme is a cognitive therapy developed to improve outcomes for individuals with persecutory delusions. It is theoretically driven, modular and personalised, with differences in ... -
Measuring Disturbance of the Endocannabinoid System in Psychosis A Systematic Review and Meta-analysis
(2019-06)Importance: The endocannabinoid system (ECS) is a lipid-based endogenous signaling system. Its relevance to psychosis is through the association between cannabis use and the onset and course of illness and through the ... -
Measuring reasoning in paranoia: Development of the Fast and Slow Thinking Questionnaire
(2020-07)Paranoid thoughts are common across the psychosis continuum. It is well established that reasoning biases (conceived as an overreliance on fast thinking and lack of willingness and/or ability to engage in slow thinking) ... -
Mental health professionals’ experiences of working with parents with psychosis and their families: a qualitative study
(2021-04)Healthcare service users who are parents with psychosis form part of the caseload of most community mental health teams. Mental health professionals can experience uncertainty about how to work with and ask about the ... -
Mindfulness and acceptance based therapies for psychosis.
(2021-06)This chapter describes two approaches—person-based cognitive therapy (PBCT) and acceptance and commitment therapy (ACT)—that belong to the group of "third-wave" or contextual cognitive-behavioral therapies (CBTs). "Thirdwave" ... -
The Needs and Experiences of Parents with Psychosis: A Qualitative Interview Study
(2022-09)Over a third of individuals diagnosed with a psychotic disorder are also a parent. The symptoms of psychosis and side effects of antipsychotic medication can impact on parents’ awareness of the needs of their children and, ... -
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ... -
Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study
(2022-06)Introduction Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated ... -
Paranoia in patients attending child and adolescent mental health services
(2021-01)OBJECTIVE: Paranoia may be particularly prevalent during adolescence, building on the heightened social vulnerabilities at this age. Excessive mistrust may be corrosive for adolescent social relationships, especially in ...
